Eidos Therapeutics to Host Symposium on TTR Stabilization at the 16th International Symposium on Amyloidosis
SAN FRANCISCO, March 20, 2018 /PRNewswire/ — Eidos Therapeutics, a clinical stage biopharmaceutical company developing AG10, a novel precision medicine for transthyretin (TTR) amyloidosis (ATTR), today announced that it will host a symposium regarding TTR stabilization at the 16th International Symposium on Amyloidosis in Kumamoto, Japan, on Thursday, March 29 from 7:40-8:40am (JST).
The symposium is titled “TTR Stabilization for ATTR: Past, Present, and Future” and will be chaired by Dr. Mathew Maurer, from Columbia University. The symposium will feature amyloidosis experts including:
- Dr. Pablo Garcia-Pavia, Hospital Universitario Puerta de Hierro Majadahonda
- Dr. Morie Gertz, Mayo Clinic
- Dr. Julian Gillmore, University College London
- Dr. Stephen Heitner, Oregon Health Sciences University
- Dr. Daniel Judge, Medical University of South Carolina
- Dr. Jose Nativi-Nicolau, University of Utah.
“This symposium brings together some of the greatest leaders in the field to discuss the role of TTR stabilizers in treating ATTR,” said Dr. Jonathan Fox, president and chief medical officer of Eidos. “As we advance our potentially best-in-class TTR stabilizer, AG10, into Phase 2 clinical trials, we will continue working closely with clinical experts and investigators, caregivers, and patients to make new treatments for TTR amyloidosis a reality.”
About AG10
AG10 is a small molecule that selectively and potently binds to and stabilizes the tetrameric transthyretin protein, preventing its dissociation into disease-causing monomers. AG10 has a unique mode of binding that mimics a naturally-occurring, disease-protective mutation. AG10 was discovered by Eidos’ co-founders Isabella Graef, MD and Mamoun Alhamadsheh, PhD, at Stanford University and the University of the Pacific, respectively.
About transthyretin amyloidosis
Transthyretin (TTR) amyloidosis is a progressive, fatal disease caused by the accumulation of misfolded TTR in multiple organ systems. Mutations in TTR destabilize the protein and predispose individuals to developing TTR amyloidosis, though the disease can also develop in older individuals without genetic mutations. Misfolded TTR is toxic to cells, and aggregated amyloid fibers can cause further organ dysfunction.
Over 250,000 people worldwide suffer from TTR amyloidosis, though the patient population may be underestimated due to its rarity and confusion with more common diseases such as heart failure. There are no FDA-approved medications indicated for the treatment of TTR amyloidosis.
About Eidos Therapeutics
Eidos Therapeutics is a clinical stage biopharmaceutical company based in San Francisco. Eidos is singularly focused on addressing the large and growing unmet need in transthyretin amyloidosis with AG10, a small molecule precision medicine that targets the disease at its source by stabilizing tetrameric transthyretin. Launched in 2016 and based on research at Stanford University, Eidos is led by a team of veteran biotechnology executives. Together with patients and physicians, the company aims to bring a safe, effective treatment to market as quickly as possible.